Patients with multiple myeloma treated with idecabtagene vicleucel, known as “ide-cel,” a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in Blood Advances.
EAE Hub model reduces barriers to early autism diagnosis
A new study led by Indiana University School of Medicine researchers shows primary care clinicians who receive specialized training can make accurate autism diagnoses for
July 18, 2023